1. Home
  2. MDGL vs TPG Comparison

MDGL vs TPG Comparison

Compare MDGL & TPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDGL
  • TPG
  • Stock Information
  • Founded
  • MDGL 2011
  • TPG 1992
  • Country
  • MDGL United States
  • TPG United States
  • Employees
  • MDGL N/A
  • TPG N/A
  • Industry
  • MDGL Biotechnology: Pharmaceutical Preparations
  • TPG Investment Managers
  • Sector
  • MDGL Health Care
  • TPG Finance
  • Exchange
  • MDGL Nasdaq
  • TPG Nasdaq
  • Market Cap
  • MDGL 6.8B
  • TPG 6.6B
  • IPO Year
  • MDGL N/A
  • TPG 2022
  • Fundamental
  • Price
  • MDGL $275.26
  • TPG $48.13
  • Analyst Decision
  • MDGL Strong Buy
  • TPG Buy
  • Analyst Count
  • MDGL 10
  • TPG 12
  • Target Price
  • MDGL $420.63
  • TPG $62.36
  • AVG Volume (30 Days)
  • MDGL 335.5K
  • TPG 2.4M
  • Earning Date
  • MDGL 05-01-2025
  • TPG 05-07-2025
  • Dividend Yield
  • MDGL N/A
  • TPG 3.62%
  • EPS Growth
  • MDGL N/A
  • TPG N/A
  • EPS
  • MDGL N/A
  • TPG N/A
  • Revenue
  • MDGL $317,383,000.00
  • TPG $3,710,887,000.00
  • Revenue This Year
  • MDGL $285.43
  • TPG N/A
  • Revenue Next Year
  • MDGL $63.77
  • TPG $24.30
  • P/E Ratio
  • MDGL N/A
  • TPG $16,303.55
  • Revenue Growth
  • MDGL N/A
  • TPG 44.34
  • 52 Week Low
  • MDGL $200.63
  • TPG $37.52
  • 52 Week High
  • MDGL $377.46
  • TPG $72.98
  • Technical
  • Relative Strength Index (RSI)
  • MDGL 38.56
  • TPG 49.12
  • Support Level
  • MDGL $265.39
  • TPG $47.20
  • Resistance Level
  • MDGL $275.54
  • TPG $48.53
  • Average True Range (ATR)
  • MDGL 11.39
  • TPG 1.28
  • MACD
  • MDGL -1.08
  • TPG -0.30
  • Stochastic Oscillator
  • MDGL 24.12
  • TPG 24.54

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

About TPG TPG Inc.

TPG Inc is an alternative asset firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, and Market Solutions. TPG aims to build dynamic products and options for its clients while also instituting discipline and operational excellence across the investment and performance of its portfolio.

Share on Social Networks: